[1]徐军伟,卢　芳,钱跃磊,等.灯盏生脉胶囊联合替格瑞洛用于急性心肌梗死经皮冠状动脉介入术后的疗效及对患者凝血功能的影响[J].新乡医学院学报,2020,37(7):622-625.[doi:10.7683/xxyxyxb.2020.07.005]
　XU Junwei,LU Fang,QIAN Yuelei,et al.Therapeutic effect of Dengzhan Shengmai capsule combined with ticagrelor in treatment of acute myocardial infarction after percutaneous coronary intervention and its effect on coagulation function of patients[J].Journal of Xinxiang Medical University,2020,37(7):622-625.[doi:10.7683/xxyxyxb.2020.07.005]
点击复制

灯盏生脉胶囊联合替格瑞洛用于急性心肌梗死经皮冠状动脉介入术后的疗效及对患者凝血功能的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年7
页码:
622-625
栏目:
临床研究
出版日期:
2020-07-05

文章信息/Info

Title:
Therapeutic effect of Dengzhan Shengmai capsule combined with ticagrelor in treatment of acute myocardial infarction after percutaneous coronary intervention and its effect on coagulation function of patients
作者:
徐军伟1; 卢　芳1 ; 钱跃磊2; 张金盈3
（1.河南省直第三人民医院药剂科，河南　郑州　450000；2.郑州煤炭工业（集团）有限责任公司总医院药剂科，河南　郑州　450000；3.郑州大学第一附属医院心血管内科，河南　郑州　450000）
Author(s):
XU Junwei1; LU Fang1; QIAN Yuelei2; ZHANG Jinying3
(1.Department of Pharmacy,the Third People′s Hospital of Henan Province,Zhengzhou 450000,Henan Province,China；2.Department of Pharmacy,the General Hospital of Zhengzhou Coal Industry (Group) Co.,Ltd.,Zhengzhou 450000,Henan Province,China;3.Department of Cardiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China)
关键词:
灯盏生脉胶囊; 替格瑞洛; 急性心肌梗死; 经皮冠状动脉介入术; 活化部分凝血活酶时间; 纤维蛋白原; D-二聚体
Keywords:
Dengzhan Shengmai capsule; ticagrelor; acute myocardial infarction; percutaneous coronary intervention; activated partial thromboplastin time; fibrinogen; D-dimer
分类号:
R542.2
DOI:
10.7683/xxyxyxb.2020.07.005
文献标志码:
A
摘要:
目的　探讨灯盏生脉胶囊联合替格瑞洛用于急性心肌梗死经皮冠状动脉介入术（PCI）后的效果及对患者血浆活化部分凝血活酶时间（APTT）、纤维蛋白原（FIB）、D-二聚体（D-D）水平的影响。方法　选择2017年6月至2019年6月于河南省直第三人民医院行PCI治疗的98例急性心肌梗死患者为研究对象。根据术后治疗方式将患者分为对照组（n=47）和观察组（n=51）。2组患者均行PCI，对照组患者PCI术后给予替格瑞洛片90 mg维持用药，每日2次；观察组患者在对照组基础上口服灯盏生脉胶囊0.36 g，每日3次。分别于术前、术后7 d检测2组患者APTT、FIB、D-D水平，分别于术前、术后2个月检测2组患者左心室每搏输出量（LVSV）、左心室心输出量（LVCO）、左心室射血分数（LVEF），记录2组患者主要心血管不良事件(MACE)及不良反应发生情况。结果　2组患者术前血浆APTT、FIB、D-D水平比较差异无统计学意义（P>0.05）；术后7 d，2组患者APTT均长于术前，FIB、D-D水平均低于术前（P<0.05）；术后7 d ，观察组患者APTT长于对照组，FIB、D-D水平低于对照组（P<0.05）。2组患者术前LVSV、LVCO、LVEF比较差异均无统计学意义（P>0.05）；2组患者术后2个月LVSV、LVCO、LVEF均高于术前（P<0.05）；术后2个月，观察组患者LVSV、LVCO、LVEF均高于对照组（P<0.05）。 观察组和对照组患者MACE发生率分别为25.53%（12/47）、7.84%（4/51），观察组患者MACE发生率显著低于对照组（P<0.05）。观察组和对照组患者不良反应发生率分别为12.77％（6/47）、15.69％（8/51），2组患者不良反应发生率比较差异无统计学意义（χ2=0.170，P>0.05）。结论　灯盏生脉胶囊联合替格瑞洛可改善急性心肌梗死患者PCI术后凝血功能、心脏功能，减少MACE，且安全性较高。
Abstract:
Objective　To evaluate the therapeutic effect of Dengzhan Shengmai capsule combined with ticagrelor in treatment of patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) and its effect on the activated partial thromboplastin time (APTT) and fibrinogen (FIB)，D-dimer (D-D) levels.Methods　Ninety-eight patients with acute myocardial infarction who underwent PCI were selected and divided into the control group (n=47) and observation group (n=51) according to the postoperative treatment method.All patients were given PCI,the patients in the control group were given ticagrelor tablets 90 mg,twice a day;the patients in the observation group were given Dengzhan Shengmai capsule 0.36 g,three times a day on the basis of the control group.The APTT and FIB and D-D levels were measured before and 7 days after operation,and the left ventricular stroke volume (LVSV),left ventricular output (LVCO) and left ventricular ejection fraction (LVEF) were measured before and 2 months after operation in the two groups.The incidence of major cardiovascular adverse events (MACE) and adverse reactions of patients in the two groups were recorded.Results　There was no significant difference in the plasma APTT,FIB and D-D levels of patients between the two groups before operation (P>0.05).The APTT of patients at 7 days after operation was longer than that before operation in the two groups(P<0.05),and the FIB and D-D levels were lower than those before operation in the two groups (P<0.05).At 7 days after operation,the APTT of patients in the observation group was longer than that in the control group(P<0.05),and the FIB and D-D levels were lower than those in the control group(P<0.05).There was no significant difference in LVSV,LVCO and LVEF of patients between the two groups before operation (P>0.05).The LVSV,LVCO and LVEF of patients at two months after operation were significantly higher than those before operation(P<0.05).The LVSV,LVCO and LVEF of patients in the observation group were significantly higher than those in the control group at two months after operation (P<0.05).The incidence of MACE of patients in the observation group and control group was 25.53%（12/47） and 7.84%（4/51）,respectively;the incidence of MACE of patients in the observation group was lower than that in the control group (P<0.05).The incidence of adverse reactions of patients in the observation group and control group was 12.77％（6/47） and 15.69％（8/51）,respectively;there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion　Dengzhan Shengmai capsule combined with ticagrelor can improve coagulation function,cardiac function of patients with acute myocardial infarction after PCI,reduce MACE,and it is safe.

参考文献/References:

［1］　AMELOOT K,DAEMEN J,VAN MIEGHEM N.PCI strategies in acute myocardial infarction with cardiogenic shock ［J］.N Engl J Med,2018,5(14):1360-1361.
［2］　MONTONE R A,NICCOLI G,MINELLI S,et al.Clinical outcome and correlates of coronary microvascular obstruction in latecomers after acute myocardial infarction ［J］.Int J Cardiol,2017,236:30-35.
［3］　常国栋,陈英伟.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI术后抗血小板治疗中的应用效果［J］.中国循证心血管医学杂志,2018,10(4):466-468.
［4］　喻露，阿依努尔，杜泽慧，等.灯盏生脉胶囊对血管性认知功能障碍患者的疗效及部分机制［J］.世界中医药，2019，14（8）:2109-2112.
［5］　李海滨,李征,胡月,等.灯盏生脉胶囊治疗冠心病及慢性心力衰竭的系统评价［J］.中西医结合心脑血管病杂志,2019,17(7):967-971.
［6］　中华医学会心血管病学分会.急性心肌梗死诊断和治疗指南［J］.中华心血管病杂志,2001,29(12):710-725.
［7］　BOATENG S,SANBORN T.Acute myocardial infarction ［J］.Dis Mon,2013,59(3):83-96.
［8］　GJESDAL K.Myocardial infarction now and then：a 50-year perspective［J］.Tidsskr Nor Laegeforen,2016,136(9):833-836.
［9］　CAPODANNO D.Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation:update ［J］.Heart,2018,104(23):1976-1983.
［10］　DUCROCQ G,STEG P G,VAN′T HOF A,et al.Utility of post-procedural anticoagulation after primary PCI for STEMI:insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials ［J］.Eur Heart J Acute Cardiovasc Care,2017,6(7):659-665.
［11］　张江武,谢志辉,侯冬子.急性心肌梗死冠状动脉介入术伴房颤患者的抗凝治疗［J］.血栓与止血学,2019,26(3):367-369.
［12］　詹小娜，包恩泽，李贵华，等.替格瑞洛联合小剂量替罗非班对行急诊经皮冠状动脉介入术老年急性ST段抬高型心肌梗死患者梗死相关动脉血流及主要不良心血管事件的影响［J］.新乡医院学报，2018，35（7）：584-587.
［13］　陈协辉,梁进杰,刘新荪,等.人参皂苷Rg1对大鼠心肌梗死后心肌血管再生的影响［J］.心血管康复医学杂志,2017,26(3):245-250.
［14］　饶小娟,吴毓敏,王彦.麦冬皂苷介导AMPK/Akt/mTOR通路对糖尿病大鼠心肌细胞自噬的影响［J］.中国循证心血管医学杂志,2018,10(11):88-93.
［15］　王文斌,菅宏伟,程国杰,等.血小板参数对急性心肌梗死患者急诊介入治疗后主要不良心脏事件的影响［J］.中国医药导报,2018,39(17):35-36.
［16］　蒋主辉,许黎莉,谢艳,等.白细胞计数与平均血小板体积比值对于急性心肌梗死患者PCI术后主要不良事件的预测价值［J］.检验医学与临床,2017,14(12):1765-1767.
［17］　宋敏,姚朱华,门剑龙,等.经皮冠状动脉介入治疗术6个月后应用低剂量替格瑞洛的有效性及安全性研究［J］.中国全科医学,2017,20(16):1973-1977.

相似文献/References:

[1]詹小娜,包恩泽,李贵华,等.替格瑞洛联合小剂量替罗非班对行急诊经皮冠状动脉介入术老年急性ST段抬高型心肌梗死患者梗死相关动脉血流及主要不良心血管事件的影响[J].新乡医学院学报,2018,35(7):584.[doi:10.7683/xxyxyxb.2018.07.009]
　ZHAN Xiao-na,BAO En-ze,LI Gui-hua,et al.Effect of ticagrelor combined with low dose tlrofiban on infarction artery blood flow & major adverse cardiovascular events elder patients with acute ST elevated myocardial infarction undergoing emerg[J].Journal of Xinxiang Medical University,2018,35(7):584.[doi:10.7683/xxyxyxb.2018.07.009]

更新日期/Last Update: 2020-07-05